1. CEO Leonard Mazur to present at Jefferies Global Healthcare Conference. 2. LYMPHIR's FDA approval in 2024 broadens CTXR's market potential. 3. Citius's pipeline includes promising therapies, enhancing investor interest. 4. Mazur will engage with institutional investors at the conference. 5. Robust IP protections bolster Citius Oncology's competitive positioning.
CTXR's upcoming presentation could attract investor interest, similar to past conferences where stocks surged post-presentation.
The presentation at a significant healthcare conference can result in immediate price fluctuations due to heightened visibility and investor engagement.
Investor sentiment may rise shortly after the June 2025 conference, influenced by discussions and potential announcements.
CRANFORD, N.J., May 5, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and its oncology subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), today announced that Leonard Mazur, Chairman and Chief Executive Officer of both companies, will present at the Jefferies Global Healthcare Conference, taking place June 3 – June 5, 2025 in New York City.
3:10 PM ET on Thursday, June 5, 2025*
New York City
A live and archived webcast of the presentation will be available here.
A replay will be available for a limited time following the presentation on the Events & Presentations portion of the Citius website www.citiuspharma.com.
In addition to the formal presentation, Mr. Mazur will participate in one-on-one meetings with institutional investors throughout the conference. Investors interested in scheduling a meeting should contact their Jefferies representative.
*Please note that the presentation date and time are subject to change. Participants should refer to the final program agenda for up-to-date information.
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns 92% of Citius Oncology. For more information, please visit www.citiuspharma.com.
Ilanit Allen [email protected] 908-967-6677 x113
STiR-communications Greg Salsburg [email protected]
SOURCE Citius Pharmaceuticals, Inc.